You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(05.20)︱中國聯通4月5G套餐用户淨增671.3萬户;人瑞人才截至4月底靈活用工人數同比增長46.6%
格隆匯 05-20 22:58

【財務數據】

百盛集團(03368.HK)一季度業績實現扭虧為盈 同店銷售升48.2%

【業績預吿】

佳明集團控股(01271.HK)盈喜:預計2021財年綜合溢利增長不少於300%

南岸集團(00577.HK)預計2021財年虧損約9.50億港元

【運營數據】

中國聯通(00762.HK)4月5G套餐用户淨增671.3萬户

人瑞人才(06919.HK)截至4月底靈活用工人數增至3.8萬人 同比增長46.6%

【增減持】

建業地產(00832.HK)獲主席兼控股股東胡葆森繼續增持300萬股

匯量科技(01860.HK)獲控股股東順流增持150.2萬股

【併購出售】

大悦城地產(00207.HK)收購中國南京土地使用權

中國玻璃(03300.HK)以9000萬元競得宿遷地塊,將用於建立生產基地

未來世界控股(00572.HK)擬4000萬港元收購香港九龍官湧街物業

台州水務(01542.HK)擬收購台州自來水、椒北供水及路橋自來水45%股權

【增發供股】

新達控股(08471.HK)控股股東擬配售最多1.666億股現有股份

中國互聯網投資(00810.HK)擬按“2供1”基準供股籌集約1901萬港元

【投資運營】

中國生物製藥(01177.HK):腫瘤治療輔助用藥“阿瑞匹坦膠囊”獲藥品註冊證書

上海醫藥(02607.HK):艾司唑侖片通過仿製藥一致性評價

石藥集團(01093.HK):抗腫瘤1類創新藥“SYHA1811片”獲中國臨牀試驗許可

復宏漢霖(02696.HK)於中華醫學會第二十五次全國風濕病學學術會議首次發佈HLX01用於類風濕關節炎治療的3期臨牀試驗數據

雲頂新耀-B(01952.HK):創新藥戈沙妥組單抗被國藥監局納入優先審評品種

中國能源建設(03996.HK)與中國鐵建簽署戰略合作框架協議

歐康維視生物-B(01477.HK):OT-101在英國提交臨牀試驗許可以啟動III期臨牀試驗獲受理

長城汽車(02333.HK):累計收到政府補助5.3億元

藥明康德(02359.HK)全資子公司擬認購私募基金份額10億元

【回購註銷】

中國燃氣(00384.HK)5月20日耗資9947萬港元回購356.7萬股

海爾智家(06690.HK)5月20日耗資4810.19萬港元回購154.4萬股

中國旺旺(00151.HK)5月18日耗資1723萬港元回購300萬股

日清食品(01475.HK)5月20日耗資298.3萬港元回購48.2萬股

中國飛機租賃(01848.HK)5月20日耗資95.1萬港元回購15.15萬股

天鴿互動(01980.HK)5月20日耗資167.43萬港元回購132.7萬股

【股權激勵】

金泰能源控股(02728.HK)授出合共1.25億份購股權

萬成金屬包裝(08291.HK)授出合共800萬份購股權

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account